Table 2.
Demographic characteristics of the studied population according to residual platelet reactivity
| Characteristics | Overall (n=180) | HTPR (n=69) | nHTPR (n=111) | P-value |
| Demographics | ||||
| Age | 64.09±11.08 | 64.91±10.47 | 63.59±11.46 | 0.434 |
| Male | 137 (76.11%) | 50 (72.46%) | 87 (78.38%) | 0.367 |
| Risk factors | ||||
| BMI (kg/m2) | 25.81±3.49 | 25.78±3.69 | 25.83±3.38 | 0.921 |
| Smoker | 54 (30.00%) | 15 (21.74%) | 39 (35.14%) | 0.046 |
| DM | 70 (38.89%) | 28 (40.58%) | 42 (37.84%) | 0.714 |
| Hypertension | 122 (67.78%) | 48 (69.57%) | 74 (66.67%) | 0.686 |
| Dyslipideamia | 78 (43.33%) | 28 (40.58%) | 50 (45.05%) | 0.557 |
| FH of CVD | 63 (35.00%) | 25 (36.23%) | 38 (34.23%) | 0.785 |
| Medication | ||||
| Clopidogrel loading dose | 42 (23.33%) | 11 (15.94%) | 31 (27.93%) | 0.068 |
| β-Receptor antagonist | 132 (73.33%) | 46 (66.67%) | 86 (77.48%) | 0.113 |
| ACEIs or ARBs | 109 (60.56%) | 40 (57.97%) | 69 (62.16%) | 0.576 |
| CCBs | 48 (26.67%) | 23 (33.33%) | 25 (22.52%) | 0.113 |
| Statins | 165 (91.67%) | 64 (92.75%) | 101 (90.99%) | 0.678 |
| PPIs | 28 (15.56%) | 11 (15.94%) | 17 (15.32%) | 0.910 |
| NSTE-ACS | 124 (68.89%) | 44 (63.77%) | 80 (72.07%) | 0.243 |
| Prior MI | 29 (16.11%) | 12 (17.39%) | 17 (15.32%) | 0.713 |
| Prior PCI | 119 (66.11%) | 47 (68.12%) | 72 (64.86%) | 0.654 |
| Platelet count (109 L−1) | 189.11±61.19 | 193.06±64.50 | 186.70±59.25 | 0.502 |
| Haematocrit (%) | 38.35±6.37 | 37.74±5.16 | 38.73±7.01 | 0.320 |
| Hemoglobin (g/L) | 133.50±18.52 | 130.40±22.43 | 133.50±18.52 | 0.319 |
Values are expressed as mean±SD or n (%). P-values refer to comparisons between HTPR and nHTPR groups. HTPR: high on-treatment platelet reactivity; nHTPR: non-high on-treatment platelet reactivity; BMI: body mass index; DM: diabetes mellitus; FH of CVD: family history of cardiovascular disease; ACEIs/ARBs: angiotensin-converting enzyme inhibitors/angiotensin receptor blockers; CCBs: calcium channel blockers; PPIs: proton pump inhibitors; NSTE-ACS: non-ST-segment elevation acute coronary syndrome; MI: myocardial infarction; PCI: percutaneous coronary intervention